Horizon Pharma plc, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; DUEXIS and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and PENNSAID for the treatment of pain of osteoarthritis of the knees. Its products also include MIGERGOT to treat vascular headache; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus and multiple other indications; and KRYSTEXXA to treat chronic refractory gout. The company has a collaboration agreement with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.
Rough day -19% on earnings Horizon Pharma Sees FY16 Rev. $1.025-$1.05B vs. Est. $1.03B, Adj. EBITDA $505-$520M
Wow, this stock got obliterated today. Could this be the bottom? There is support from October 22nd at this level, and a massive sell-off with high volume today. @Gil Oren, you may want to fix the thread title with the symbol HZNP
Reported before open today (5/9/16) Earnings: EPS $0.34 Revenue $204.7M Estimates: EPS $0.30 Revenue $197.73M Up 13.87% today
Reported before open today (11/7/16) Earnings: EPS $0.70 Revenue $273.7M Estimates: EPS $0.63 Revenue $270.04M Up 14.02% today
